LEVEL 38, MELBOURNE, VICTORIA, C3
Corporate Governance Statement Approved by Board
Receives FDA Approval for New Potency Assay to Release Commercial Product
REPORTS SUBSTANTIAL REVENUE GROWTH TO US$120M Market Share Expands; Phase 3 Back Pain Trial Completes Treatment
Appendix 3G - Notification of Issue, Conversion or Payment Up of Unquoted Equity Securities
Financial Results and Corporate Update Webcast
Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
Material disclosure
.3
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis